Insight Molecular Diagnostics Inc. (IMDX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Oil slips but stays near six-month highs on Saudi attacks
Tweet
Share
E-mailGet Alerts IMDX Hot Sheet
Join SI Premium – FREE
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) reported Q2 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $470.85 thousand.
For earnings history and earnings-related data on Insight Molecular Diagnostics Inc. (IMDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sierra Bancorp (BSRR) Tops Q3 EPS by 27c
- Verizon Communications (VZ) Tops Q3 EPS by 3c; offers guidance
- Needham Recaps Week 7 of NFL Season Impact, Says CapOne Replaced Kalshi at #1 on Finance App Store
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
